Cancer is one of the leading causes of death worldwide, yet many types still don’t have regular screening programs. Even when screening is available, many people at higher risk find the tests difficult or uncomfortable to follow. Newer blood-based tests, like liquid biopsies, are showing promise for early detection of cancers. Liquid biopsy is a method where circulating tumor DNA (ctDNA) shed from the tumor is extracted and sequenced. This unveils the necessary information regarding cancer causing mutations in the related genes enhancing clinicians to decide the best course of treatment.
G2M offers a panel for liquid biopsy covering major cancer types like Lung, Breast and Colorectal cancer. This panel gives a detailed insight on cancer-related genes to uncover known as well as novel variants for further investigation.
Key features & highlights:
Colorectal Cancer Care with Liquid Biopsy & NGS Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. Liquid biopsy, particularly when combined with Next-Generation Sequencing (NGS), has emerged as a powerful non-invasive strategy for molecular profiling, therapy guidance, and disease monitoring in CRC.
| Features | Performance |
|---|---|
| Coverage uniformity (0.2X) | >99% |
| Reproducibility (%) | 95.5 |
| Sensitivity (%) | 93.7 |
| On Target Ratio (%) | 70-85 |
| Parameter | Description |
| Gene count | 25 |
| Covered region | Whole CDS |
| Target size | 75 Kb |
| Mutation types | SNV / InDels / CNV |
| Sample type | Blood / Plasma |
| Platform compatibility | Illumina, Thermo Fisher (Ion Torrent), MGI, Element Biosciences |
| Bioinformatics Support: | Primary Analysis: FASTQ to annotated VCF Secondary Analysis: CNVs, SNVs, InDel, Fusions Tertiary Analysis: Clinical interpretation |
| Type of Cancer | Gene | Drug |
|---|---|---|
| Colorectal Cancer | EGFR | Cetuximab, Panitumumab |
| Colorectal Cancer | KRAS | Cetuximab, Panitumumab |
| Gastric and gastroesophageal cancer | ERBB2 | Trastuzmab |
The ctDNA Colorectal Cancer Panel examines critical genes associated with cancer progression and therapeutic outcomes. The table below enumerates the key genes interrogated by the assay, along with their associated molecular pathways and potential targeted therapeutic interventions.
| Commercial Name | Cat No. | Pack Size | Platform |
|---|---|---|---|
| ctDNA Colorectal NGS Test Kit | G710029-1 | 24 T | Illumina |
| G710029-2 | 96 T | Illumina | |
| G710029-3 | 96 T – EZY | Illumina – EZY | |
| ctDNA Colorectal NGS Test Kit | G710029-4 | 24 T | MGI |
| G710029-5 | 96 T | MGI | |
| G710029-6 | 96 T – EZY | MGI – EZY | |
| ctDNA Colorectal NGS Test Kit | G710029-7 | 24 T | Aviti |
| G710029-8 | 96 T | Aviti | |
| G710029-9 | 96 T – EZY | Aviti – EZY | |
| ctDNA Colorectal NGS Test Kit | G710029-10 | 24 T | Thermo |
| G710029-11 | 96 T | Thermo | |
| G710029-12 | 96 T – EZY | Thermo – EZY |
Download useful documents and technical information of Liquid Biopsy ctDNA Colorectal.
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
All products listed in the catalogue are the products of Genes2Me Private Limited. Apart from that, all other product names, trademarks and logos wherever used in the catalogue are the property of their respective owners.
© 2025 Genes2me. All rights reserved.
